对真菌感染进行药物重新定位
Anshu Mathuria1, Namra Ali2, Naina Kataria1
1Department of Biochemistry, Sri Venkateswara College, University of Delhi, New Delhi, India.
Progress in molecular biology and translational science
|June 28, 2024
概括
耐多药性真菌感染构成了全球健康威胁. 药物再利用提供了一个有希望的,具有成本效益的战略,以打击这些耐药菌株,并开发新的抗真菌疗法.
科学领域:
- 医学真菌学 医学真菌学
- 传染性疾病 传染性疾病
- 药物发现 药物发现 药物发现
背景情况:
- 耐多药细菌和真菌代表着一个重要的全球卫生挑战,由世界卫生组织优先考虑.
- 像Candida和Aspergillus这样的特定真菌物种对许多抗真菌药物表现出内在的耐药性,导致临床结果差.
- 开发新型抗真菌药物是耗时和昂贵的,需要替代治疗策略.
研究的目的:
- 提供当前抗真菌药物及其抗药性机制的全面概述.
- 探索药物重定向作为抗真菌治疗的快速和经济有效的解决方案的潜力.
- 研究用于治疗耐药真菌感染的非传统药物的抗菌性质.
主要方法:
- 对当代抗真菌剂及其耐药性概况的文献综述.
- 对抗真菌应用的药物重用策略的分析.
- 探索非传统化合物的抗菌性质.
主要成果:
- 在常见的真菌病原体中确定了关键的耐药机制.
- 强调药物重用作为解决抗真菌耐药性的可行和快速方法.
- 展示了非传统药物对抗耐药真菌感染的潜力.
结论:
- 药物再利用为开发抗药性真菌感染的新疗法提供了具有成本效益和安全性的替代方案.
- 对现有和新型抗真菌剂的整体理解对于有效管理具有挑战性的真菌病至关重要.
- 对药物再利用和非传统抗微生物药物的持续研究对于打击抗真菌耐药性日益增长的威胁至关重要.
相关概念视频
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Fungal Phylum Microsporidia
Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...


